Thomas VanCott

Dr. VanCott is the Chief Technology & Strategy Officer for Catalent Cell & Gene Therapy, a CDMO manufacturing viral vectors for gene and cell therapies based in the US and Europe. He is responsible for strategically enhancing and augmenting CMC services to meet the market demand of increasingly complex cell and gene therapy products. He also leads the product development and internal R&D teams. Prior to this, he was the CEO for 10 years at another Maryland-based CMO/CRO (ABL) where he was responsible for the strategic international growth of the company. He has been involved in virus and biologic product development for over 25 years. He has a PhD in physical chemistry and started his career as a Captain in the US Army stationed at Walter Reed Army Institute of Research (WRAIR) studying and developing HIV vaccines for international deployment from initial construction through preclinical development and GMP manufacturing to clinical trials.